1. Fostemsavir to overcome drug–drug interactions in heavily treatment-experienced people with HIV and cancer.
- Author
-
Giacomelli, Andrea, Cattaneo, Dario, Pozza, Giacomo, Moschese, Davide, Cossu, Maria Vittoria, Dalu, Davide, and Gervasoni, Cristina
- Subjects
- *
ORGANIC anion transporters , *RALTEGRAVIR , *HIV-positive persons , *CANCER patients , *DRUG interactions , *RITONAVIR , *HIGHLY active antiretroviral therapy , *CANCER chemotherapy - Abstract
This article discusses the use of fostemsavir, a first-in-class attachment inhibitor, to overcome potential drug-drug interactions (pDDIs) between chemotherapy and boosted protease inhibitors (bPIs) in heavily treatment-experienced people with HIV (PWH) and cancer. The authors present two cases of PWH with solid malignancies who were able to undergo first-line chemotherapy with the use of fostemsavir to avoid pDDIs. The authors suggest that fostemsavir provides an additional option for constructing a suppressive antiretroviral regimen in PWH with cancer, but caution that strict virological monitoring is necessary. They also mention the potential for fostemsavir to increase the exposure of paclitaxel, a chemotherapy drug, and advise clinicians to monitor for potential paclitaxel-related toxicity in PWH treated with fostemsavir. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF